Roche Bulks Up In NLRP3 With €380m Inflazome Buy

Irish Biotech A Pioneer In Inflammasomes

Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.

Inflazome
Hands full: CEO Matt Cooper with Inflazome colleagues • Source: Inflazome

Just four years after its foundation, Ireland's Inflazome Ltd. and its portfolio of NLRP3 inhibitors targeting a wide range of chronic inflammatory conditions has been acquired by Roche Holding AG.

The Swiss major has splashed out €380m upfront to buy the firm which was founded in 2016 by Matt Cooper from the University of Queensland, Australia and Luke O'Neill from Trinity College in Dublin

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By 

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.